Cold Email That Actually Lands With Biotech Buyers.
Leadriver writes, launches, and optimises cold email campaigns for the Biotech market: reaching VP Business Development, Heads of Commercial, Chief Scientific Officers, and Licensing Directors with sequences that get opened, get read, and get replies.
48%
6.2%
Average reply rate
10
Days to campaign launch
18+
Industries served
Why Biotech Outbound Fails for Most Teams
Life sciences buyers are highly selective and sceptical of outreach from vendors who do not understand clinical development timelines, regulatory pathways, or scientific rigour.
We write sequences that reference clinical development context, regulatory timelines, and scientific credibility: the language that opens doors in life sciences.
Life sciences purchasing often follows clinical or regulatory milestones. Without ongoing outbound activity aligned to those timelines, you miss the windows when buyers have budget and mandate to act.
We identify the right buyer at each company based on their development stage and your product's position in the value chain.
Biotech sales cycles are among the longest in B2B. Building internal outbound capability for this audience requires domain expertise that is rare and expensive to hire.
Every meeting handoff includes the prospect's pipeline context and development stage so your team leads with a precisely relevant case.
The right buyer in a life sciences organisation depends on whether the product touches R&D, clinical operations, regulatory affairs, or commercial launch. Each function has different priorities and different vocabulary.
We have run over 2,000 outbound campaigns across 18 industries and generated more than 85,000 interested leads. Our team understands the Biotech market and writes accordingly.
How We Build and Run Your Biotech Cold Email Campaigns
Domain Setup and Technical Foundation
We handle all technical setup: sending domains, MX records, SPF, DKIM, DMARC, and inbox warm-up. We run a minimum 14-day warm-up before any Biotech sequence goes live to protect deliverability.
Biotech Sequence Writing and A/B Testing
We write multi-step email sequences tailored to biotech buyers pain points and timed around clinical trial phase transitions, regulatory submissions, commercial launch preparation, and partnership or licensing rounds. Two variants launch from day one so we start optimising from the first reply.
Campaign Launch and Inbox Management
All sending is managed by our team across rotating inboxes. We monitor deliverability daily, handle replies, and qualify interested biotech buyers before they reach your calendar.
Optimisation and Weekly Reporting
Every week we review open rates, click rates, and reply rates by sequence and variant. Underperforming copy gets rewritten. What is working gets scaled. You get a clear weekly dashboard.
What Cold Email Delivers in the Biotech Market
in 90 days
For a clinical data management platform targeting VP Clinical Operations and Heads of Data Management at Phase II and III biotech companies across Europe.
Clinical Data / Biotech
in two quarters
A regulatory submission platform targeting Heads of Regulatory Affairs at mid-size specialty pharma companies generated two enterprise contracts from a 180-day programme.
Regulatory Tech / Biotech
to first meeting
A clinical trial management platform booked its first qualified VP Clinical Operations conversation within 16 days of launching outbound.
CTMS / Biotech
Questions About Cold Email for Biotech
Cold Email That Works for Biotech.
Book a discovery call and we will show you your addressable market, expected deliverability benchmarks for your industry, and what a realistic cold email programme looks like.
Book Your Discovery Call